RT Journal Article
SR Electronic
T1 Sarcoidosis complicating treatment with natalizumab for Crohn's disease
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 1109
OP 1110
DO 10.1136/thx.2010.155762
VO 66
IS 12
A1 Parisinos, C A
A1 Lees, C W
A1 Wallace, W A H
A1 Satsangi, J
YR 2011
UL http://thorax.bmj.com/content/66/12/1109.abstract
AB Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.